OptiBiotix Health (LSE:OPTI) 3-Year Revenue Growth Rate : -5.90% (As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is OptiBiotix Health 3-Year Revenue Growth Rate?

OptiBiotix Health's Revenue per Share for the six months ended in Jun. 2023 was £0.00.

During the past 12 months, OptiBiotix Health's average Revenue per Share Growth Rate was -46.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was -5.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 30.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of OptiBiotix Health was 125.70% per year. The lowest was -5.90% per year. And the median was 58.70% per year.

Competitive Comparison of OptiBiotix Health's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, OptiBiotix Health's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptiBiotix Health's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OptiBiotix Health's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where OptiBiotix Health's 3-Year Revenue Growth Rate falls into.

OptiBiotix Health 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

OptiBiotix Health (LSE:OPTI) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

OptiBiotix Health 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of OptiBiotix Health's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiBiotix Health (LSE:OPTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OptiBiotix Health PLC (LSE:OPTI) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

OPTI.GB:UK OB3:Germany

Address

Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG

Website

https://www.optibiotix.com

OptiBiotix Health PLC is engaged in the field of healthcare. As a life science company, its prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company derives majority of the revenue from the sale of Functional Fibres. The company markets its products in the United Kingdom under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.